PER312
Congenital Sucrase-Isomaltase Deficiency (CSID)
PreclinicalActive
Key Facts
Indication
Congenital Sucrase-Isomaltase Deficiency (CSID)
Phase
Preclinical
Status
Active
Company
About Perseo Pharma
Perseo Pharma is a Swiss biotech developing next-generation enzyme replacement therapies using its proprietary nano-shield platform. The company's technology encapsulates enzymes in silica-based nanoparticles with muco-adhesive coatings, enhancing intestinal residence time and activity while remaining non-systemic. Its pipeline targets digestive enzyme deficiencies like EPI and rare metabolic disorders, with a strategic R&D collaboration with Nestlé Health Science providing validation and resources. Founded in 2019, the company is privately held and currently in the preclinical stage.
View full company profileTherapeutic Areas
Other Congenital Sucrase-Isomaltase Deficiency (CSID) Drugs
| Drug | Company | Phase |
|---|---|---|
| Sucraid® (sacrosidase) Oral Solution | QOL Medical | Approved |